| # | Drug | Count |
|---|---|---|
| 0 | FUROSEMIDE | 598 |
| 1 | METHOTREXATE SODIUM | 540 |
| 2 | METHOTREXATE | 514 |
| 3 | DEXAMETHASONE | 492 |
| 4 | DEXAMETHASONE 1.5 MG | 491 |
| 5 | CYCLOPHOSPHAMIDE | 467 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 467 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 467 |
| 8 | PREDNISOLONE | 406 |
| 9 | PREDNISOLONE ORAL | 406 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ZOLBETUXIMAB | 129 | 0.0846 |
| 1 | DINUTUXIMAB | 55 | 0.0640 |
| 2 | TAGRAXOFUSP | 25 | 0.0465 |
| 3 | LAZERTINIB | 24 | 0.0277 |
| 4 | VANCOMYCIN HYDROCHLORIDE | 219 | 0.0262 |
| 5 | AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT) | 8 | 0.0261 |
| 6 | CALASPARGASE PEGOL | 16 | 0.0199 |
| 7 | ALBUMIN HUMAN | 96 | 0.0193 |
| 8 | IDECABTAGENE VICLEUCEL | 22 | 0.0177 |
| 9 | ALBUMIN (HUMAN) | 96 | 0.0175 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 1521 |
| 1 | Platinum-based Drug [EPC] | 855 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 841 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 831 |
| 4 | Loop Diuretic [EPC] | 653 |
| 5 | Alkylating Drug [EPC] | 605 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 598 |
| 7 | Kinase Inhibitor [EPC] | 562 |
| 8 | Proton Pump Inhibitor [EPC] | 516 |
| 9 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 449 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 129 | 0.0846 |
| 1 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 55 | 0.0507 |
| 2 | CD123 Interaction [EPC] | 25 | 0.0465 |
| 3 | Endoglycosidase [EPC] | 25 | 0.0135 |
| 4 | CD19-directed Chimeric Antigen Receptor [EPC] | 114 | 0.0112 |
| 5 | Asparagine-specific Enzyme [EPC] | 127 | 0.0094 |
| 6 | Human Blood Coagulation Factor [EPC] | 6 | 0.0073 |
| 7 | CD38-directed Cytolytic Antibody [EPC] | 42 | 0.0072 |
| 8 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 29 | 0.0072 |
| 9 | Tubulin Inhibiting Agent [EPC] | 2 | 0.0069 |